

REMARKS

Reconsideration of this application is requested in view of the amendments to the claims and the remarks presented herein.

The claims in the application are claims 1 to 7 and 11, all other claims having been cancelled.


Claims 1, 6, 7 and 11 were rejected under 353 USC 112, second paragraph, and claims 2 to 5 were objected to as being dependent upon a rejected base claim. The Examiner objected to the “ring system” at the end of the B definition as being unclear and to the use of 5' as a subscript in the definition of R_2 .

Applicants respectfully traverse these grounds of rejection since the amended claims are believed to properly define the invention. The “ring system” at the end of the B definition has been deleted and the use of 5 subscript prime has been corrected in the definition of R_2 . Therefore, withdrawal of these grounds of rejection is requested.

The specification was objected to in lines 8 and 9 of page 4 as being improper since reference applications was not proper but only publications may appear. It is believed that the Examiner is incorrect in the objection thereto since all of the applications referred to have been published and therefore, reference to them is proper. In fact, PCT/FR98/08051 and PCT/EP99/00242 were published before filing of the present application as can be seen from copies of the first page of each filed herewith.

In view of the amendments to the claims and the above remarks, it is believed that the claims clearly point out Applicants' patentable contribution and favorable reconsideration of the application is requested.

Respectfully submitted,
Muserlian, Lucas and Mercanti



Charles A. Muserlian, 19,683
Attorney for Applicants
Tel. # (212) 661-8000

CAM:ds
Enclosures

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 239/16, C07C 311/19, A61K 31/505		A1	(11) International Publication Number: WO 99/37621
			(43) International Publication Date: 29 July 1999 (29.07.99)
(21) International Application Number: PCT/EP99/00242		(54) Title: NOVEL SULFONAMIDE DERIVATIVES AS INHIBITORS OF BONE RESORPTION AND AS INHIBITORS OF CELL ADHESION	
(22) International Filing Date: 16 January 1999 (16.01.99)			
(30) Priority Data: 09/012,489 23 January 1998 (23.01.98) US			
(71) Applicants (for all designated States except US): HOECHST MARION ROUSSEL, DEUTSCHLAND GMBH (DE/DE); Brühningstrasse 50, D-65929 Frankfurt am Main (DE); GENENTECH, INC. (US/US); 1 DNA Way, South San Francisco, CA 94080-4990 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(72) Inventors; and (75) Inventors/Applicants (for US only): PEYMAN, Anuschirwan (DE/DE); Zeilshelmer Strasse 46, D-65779 Kelkheim (DE); WILL, David, William (GB/DE); Taunusstrasse 9A, D-65824 Schwalbach (DE); KNOLLE, Jochen (DE/DE); Höchster Strasse 21, D-65830 Kriftel (DE); SCHREINE-MANN, Karlheinz (DE/DE); Im Kohlruß 11, D-65835 Niederbach (DE); CARNIATO, Denis (FR/FR); 10, avenue de l'Étang-Neuf, F 91460 Marcoussis (FR); GOUR-VEST, Jean François (FR/FR); 12, rue de la Bilconne, F-77410 Clayc Souilly (FR); GADEK, Thomas (US/US); 2838 Chelsea Drive, Oakland, CA 94611 (US); MCDOW-ELL, Robert (US/US); 1264 Church Street, San Francisco,		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
<p style="text-align: right;">(I)</p>			
(57) Abstract			
<p>The present invention relates to sulfonamide derivatives of formula (I), in which R¹, R², R⁴, R⁵ and R⁶ have the meanings indicated in the claims, their physiologically tolerable salts and their prodrugs. The compounds of the formula (I) are valuable pharmaceutical active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and inhibit bone resorption by osteoclasts. They are suitable, for example, for the therapy and prophylaxis of diseases which are caused at least partially by an undesired extent of bone resorption, for example of osteoporosis. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as pharmaceutical active ingredients, and pharmaceutical preparations comprising them.</p>			

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 239/16, C07C 279/20, A61K 31/505	A1	(11) International Publication Number: WO 99/32457 (43) International Publication Date: 1 July 1999 (01.07.99)
(21) International Application Number: PC1/EP98/08051 (22) International Filing Date: 10 December 1998 (10.12.98) (30) Priority Data: 97122520.6 19 December 1997 (19.12.97) EP (71) Applicants (for all designated States except US): HOECHST MARION ROUSSEL DEUTSCHLAND GMBH (DE/DE); Bruningstrasse 50, D-65929 Frankfurt am Main (DE); GENENTECH, INC. (US/US); 1 DNA Way, South San Francisco, CA 94080-4990 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): PEYMAN, Anuschirwan (DE/DE); Zeilsheimer Strasse 46, D-65779 Kelkheim (DE); KNOLLE, Jochen (DE/DE); Höchststrasse 21, D-65830 Kriefel (DE); BREIPOHL, Gerhard (DE/DE); Goisenheimer Strasse 95, D-60529 Frankfurt (DE); SCHNEUNEMANN, Karl-Heinz (DE/DE); Im Kuliruss 11, D-65835 Liederbach (DE); CARNIATO, Denis (FR/FR); 10, avenue de l'Etang Neuf, F-91460 Marcoussis (FR); GOURVEST, Jean-François (FR/FR); 12, rue de la Biberonne, F-77140 Claye Souilly (FR); GADEK, Thomas (US/US); 2838 Chelsea Drive, Oakland, CA 94611 (US); MCDOWELL, Robert (US/US); 1264 Church Street, San Francisco, CA		24114 (US); BODARY, Sarah, Catherine [US/US]; 3530 Crestmoor Drive, San Bruno, CA 94066 (US); CUTHBERTSON, Robert, Andrew [AU/AU]; 75 Rae Street, North Fitzroy, VIC 3068 (AU); FERRARA, Napoleone [US/US]; 2090 Pacific Avenue #704, San Francisco, CA 94109 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BE, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW. ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NI, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.
(54) Title: NOVEL ACYLGUANIDINE DERIVATIVES AS INHIBITORS OF BONE RESORPTION AND AS VITRONECTIN RECEPTOR ANTAGONISTS <div data-bbox="344 1180 1230 1386" data-label="Chemical-Block"> $\begin{array}{c} \text{R}^4\text{-O-C(=O)-CH}_2\text{-CH}_2\text{-NH-C(=O)-N(R}^1\text{)-C(=O)-N(R}^2\text{)-R}^6 \\ \text{O=C-NH-O-R}^5 \end{array} \quad (I)$ </div> (57) Abstract <p>The present invention relates to acylguanidine derivatives of formula (I) in which R¹, R², R⁴, R⁵, R⁶, A, m and n have the meanings indicated in the patent claims, their physiologically tolerable salts and their prodrugs. The compounds of formula (I) are valuable pharmaceutical active ingredients. They are vitronectin receptor antagonists and inhibitors of bone resorption by osteoclasts and are suitable, for example, for the therapy or prophylaxis of diseases which are caused at least partially by an undesired extent of bone resorption, for example of osteoporosis. The invention furthermore relates to processes for the preparation of compounds of formula (I), their use, in particular as pharmaceutical active ingredients, and pharmaceutical preparations comprising them.</p>		